Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $293.00

Alnylam Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • BMO Capital Markets raised its price target on Alnylam from $292 to $293 and maintained an “outperform” rating, implying 94.7% upside from the prior close.
  • Analyst views are mixed: the consensus is “Moderate Buy” with a $287.70 target, while several firms recently cut their targets or ratings.
  • Regeneron’s FDA approval of a therapy developed with Alnylam is expected to bring Alnylam a $25 million milestone payment plus royalties; it marks the seventh FDA-approved therapy from Alnylam’s RNAi platform.
  • MarketBeat previews top five stocks to own in December.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective lifted by equities research analysts at BMO Capital Markets from $292.00 to $293.00 in a report issued on Friday, Benzinga reports. The firm currently has an "outperform" rating on the biopharmaceutical company's stock. BMO Capital Markets's price objective would suggest a potential upside of 94.71% from the stock's previous close.

Other research analysts also recently issued research reports about the stock. Morgan Stanley decreased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an "equal weight" rating for the company in a research report on Friday, October 30th. HC Wainwright dropped their target price on shares of Alnylam Pharmaceuticals from $455.00 to $250.00 and set a "buy" rating on the stock in a report on Tuesday. Sanford C. Bernstein cut shares of Alnylam Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $376.00 to $199.00 in a report on Friday, October 30th. Jefferies Financial Group raised their target price on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a "hold" rating in a research note on Tuesday, September 8th. Finally, Canaccord Genuity Group reduced their price target on Alnylam Pharmaceuticals from $429.00 to $323.00 and set a "buy" rating for the company in a report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $287.70.

Read Our Latest Research Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Up 1.8%

Shares of Alnylam Pharmaceuticals stock traded up $2.66 on Friday, reaching $150.48. 429,373 shares of the company were exchanged, compared to its average volume of 1,613,461. The company has a market capitalization of $20.16 billion, a price-to-earnings ratio of 7.80 and a beta of 0.42. The company has a current ratio of 2.48, a quick ratio of 2.43 and a debt-to-equity ratio of 0.18. Alnylam Pharmaceuticals has a one year low of $146.51 and a one year high of $479.79. The company has a 50-day moving average of $210.88 and a 200 day moving average of $272.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating the consensus estimate of $1.66 by $14.60. The business had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The firm's revenue was up 16.7% on a year-over-year basis. During the same period last year, the business earned $2.90 earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post 6.85 earnings per share for the current year.

Insider Activity

In related news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president owned 12,807 shares of the company's stock, valued at $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of the stock. SCS Capital Management LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $34,784,000. WINTON GROUP Ltd acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $2,372,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $50,773,000. Silvant Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $5,456,000. Finally, Wealthfront Advisers LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $2,876,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Alnylam Pharmaceuticals

Here are a few of the latest stories about ALNY:

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

See Also

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?

Before you consider Alnylam Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.

While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines